• Mashup Score: 5
    Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC - 3 year(s) ago

    In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. We report 5-year efficacy and safety follow-up for the KEYNOTE-010 study.

    Source: Journal of Thoracic Oncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JTOonline
      JTOonline

      A #JTO paper describes how in the KEYNOTE-010 study, #pembrolizumab improved overall survival vs docetaxel in patients w/previously treated, advanced #NSCLC w/PD-L1 tumor proportion score ≥50% & ≥1%. More: https://t.co/P4mktoUatF @YaleCancer @DrRoyHerbstYale #pembrolizumab https://t.co/EMAinszo88

    • Profile photo of IASLC
      IASLC

      A #JTO paper describes how in the KEYNOTE-010 study, #pembrolizumab improved overall survival vs docetaxel in patients w/previously treated, advanced #NSCLC w/PD-L1 tumor proportion score ≥50% & ≥1%. More: https://t.co/uFH4pHr2U2 @YaleCancer @DrRoyHerbstYale #pembrolizumab https://t.co/1BNvlyMSna

  • Mashup Score: 3
    Cardiac Toxicity of Lung Cancer Radiotherapy | IASLC - 3 year(s) ago

    This scenario is not uncommon; at least one-quarter of patients treated for lung cancer have pre-existing cardiovascular disease (CVD). Given improved outcomes …

    Source: IASLC
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of IASLC
      IASLC

      A recent paper in @JTOonline summarizes the growing evidence around the cardiac toxicity of radiotherapy in patients with lung cancer, and provides answers to several related questions... https://t.co/5jKHmtAraP #LCSM #JTO #Radiotherapy

  • Mashup Score: 3
    KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From the In Vitro Experiments - 3 year(s) ago

    KRAS mutations have been recognized as undruggable for many years. Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being developed in clinical trials and have revealed promising results in metastatic NSCLC. Nevertheless, it is strongly anticipated that acquired resistance will limit their clinical use. In this study, we developed in vitro models of the KRAS G12C cancer,…

    Source: Journal of Thoracic Oncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JTOonline
      JTOonline

      In a study published in @JTOonline Koga & @t_mitsudomi et al. develop in vitro models of KRAS G12C, derived from resistant clones against sotorasib & adagrasib, & search for secondary KRAS mutations as on-target resistance mechanisms. #JTO #LCSM https://t.co/sTxjyCBZ4R @IASLC https://t.co/wQncsxiJhq

    • Profile photo of IASLC
      IASLC

      In a study published in @JTOonline Koga & @t_mitsudomi et al. develop in vitro models of KRAS G12C, derived from resistant clones against sotorasib & adagrasib, & search for secondary KRAS mutations as on-target resistance mechanisms. #JTO #LCSM https://t.co/7qrBRHdMty https://t.co/cicZQ4ZJyp

  • Mashup Score: 0
    JTO - March 2021 - 3 year(s) ago

    So the New Year certainly started with a bang… not due to the fireworks that had all been cancelled but courtesy of the ‘New Variant’ of an ‘Old Foe’. We were straight back into the thick of things and recovery is only just starting but there are some green shoots of spring appearing and reasons to be cheerful.

    Source: www.boa.ac.uk
    Categories: Latest Headlines, Orthopedics
    Tweet Tweets with this article
    • Profile photo of BritOrthopaedic
      BritOrthopaedic

      Take a look at our brand edition of this month’s #JTO. This issues focusses on soft-tissue problems around the knee joint and much more. To view, please visit https://t.co/gybXjZNPhv #orthotwitter #trauma #orthopaedics https://t.co/C9n88c8ECm

  • Mashup Score: 0
    Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy - 3 year(s) ago

    In 2018, durvalumab was approved by the U.S. Food and Drug Administration as consolidation immunotherapy for patients with stage III NSCLC after definitive chemoradiotherapy (CRT). However, whether durvalumab benefits patients with EGFR-mutated NSCLC remains unknown.

    Source: Journal of Thoracic Oncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JTOonline
      JTOonline

      Aredo JV et al. report on multi-institutional retrospective analysis of pts. with unresectable stage III #EGFR #NSCLC who completed concurrent #CRT. https://t.co/2RsGFQ39Sw #JTO #JTOCRR #LCSM @IASLC @HwakeleeMD https://t.co/4LiqshwsH5

    • Profile photo of IASLC
      IASLC

      Aredo JV et al. report on multi-institutional retrospective analysis of pts. with unresectable stage III #EGFR #NSCLC who completed concurrent #CRT. https://t.co/VbZTeo1LCj #JTO #JTOCRR #LCSM @JTOonline @HwakeleeMD https://t.co/vOhPZsiymE

  • Mashup Score: 2
    Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions - 3 year(s) ago

    The impact of radiotherapy on the heart has become an area of interest in recent years. Many different cardiac dose-volume constraints have been associated with cardiac toxicity and survival; however, no consistent constraint has been found. Many patients undergoing treatment for lung cancer have risk factors for cardiovascular disease or known cardiac comorbidities; however, there is little…

    Source: Journal of Thoracic Oncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JTOonline
      JTOonline

      Banfill et al. provide a summary of the existing literature on cardiac toxicity of lung cancer radiotherapy, propose strategies to avoid and manage cardiac toxicity, and suggest avenues for future research. #JTO #JTOCRR @IASLC https://t.co/xfqGDyyEUZ https://t.co/jzRbJzYgS9

  • Mashup Score: 0
    The feasibility and safety of routine thoracic surgeries in the low risk areas during the COVID-19 pandemic - 3 year(s) ago

    Corona virus disease 2019 (COVID-19) has been under good control and work resumption has been gradually carried out in most parts of China including Shanghai after March 2020. However, intense focus and resources have been diverted to COVID-19 patients, leaving patients with diseases other than COVID-19 somehow neglected due to limited access to routine health care. And whether routine thoracic…

    Source: JTO Clinical and Research Reports
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JTOonline
      JTOonline

      Wang et al. retrospectively analyzed the quantity & quality of thoracic surgeries performed by a single team from Shanghai Chest Hospital between Jan. & May 2020, compared with the corresponding period last year. Read the article. @IASLC #JTO #LCSM https://t.co/vuslEM4pjZ https://t.co/mhUn7BUVhb

Load More